After Glaxo's genital herpes vaccine flop, check out Agenus Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : After Glaxo's genital herpes vaccine flop, check out Agenus

GSK 46.86

-0.2%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: robert b furman who wrote (21)	5/1/2015 5:17:58 AM
From: robert b furman	of 22

GSK making some excellent inroads to struggling N America market: U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug 11 hours ago ? ? ? ? Content preferences Done [iframe tabindex="-1" id="yom-ad-LREC-iframe" src="http://l.yimg.com/rq/darla/2-8-8/html/r-sf.html" frameborder="no" marginwidth="0" marginheight="0" scrolling="no" style="left: 0px; top: 0px; width: 300px; height: 250px; display: block; visibility: inherit; position: absolute; z-index: 10;" hidefocus="true" allowtransparency="true" async=""][/iframe] Related Quotes GSK.L1,498.50-1.06% THRX16.25-4.80% GlaxoSmithKline plc? Watchlist 1,498.50-16.00(1.06%) London3:46AM EST U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug Reuters 11 hrs ago GSK wins approval for asthma drug; will be produced in Zebulon American City Business Journals q 11 hrs ago More Theravance Inc.? Watchlist 16.25-0.82(4.80%) NASDAQThu, Apr 30, 2015 4:00 PM EDT April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger asthma sufferers. The agency, in a so-called complete response letter, told the companies that additional data would be required to further demonstrate Breo's safety and efficacy in that population. The FDA's decision came after an FDA advisory panel of experts had voted 16-4 that Breo Ellipta should be approved for use by adults. It voted 19-1 that available data did not support approval for use in children aged 12 to 17.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext